| What is the product best at? |
Mature workout logging, history, analytics, templates, exercise library, timers, Apple Watch, and self-directed progression support. |
History-aware Session Plans, explicit targets, post-workout review, progression guidance, and explanation around the next training decision. |
| Who owns progression decisions? |
The athlete mostly decides what to do next, using Strong's previous performance, records, charts, and workout history. |
Oved proposes targets and next actions from logged evidence, while keeping the athlete able to inspect, adjust, and review the recommendation. |
| Gym-floor logging |
Excellent. Strong's fast previous-to-actual-to-complete flow is a genuine benchmark. |
Built around previous context, target, actual result, and completion. The target must earn the extra attention it asks for. |
| History and analytics |
Strong. Exercise history, charts, records, volume, estimated 1RM, PRs, and calendar/profile views are real product strengths. |
History is treated as coaching evidence: sessions, targets, logged sets, reviews, and Exercise Intelligence stay connected. |
| Workout review |
Completion is factual and lightweight: what you logged, records, duration, volume, and history. |
Completed workouts are reviewed against targets and evidence so the athlete can see what happened and what should happen next. |
| Wearables and integrations |
Clear current advantage: Apple Watch, Live Sync, Apple Health, Live Activity/Dynamic Island rest-timer support, Android and Google Play presence. |
Native mobile is the current gym-floor focus, but Oved should not claim Strong-level Watch or ecosystem maturity today. |
| Migration |
Strong supports CSV export. Strong's own help says exported CSV cannot be imported back into Strong. |
Oved supports Strong CSV import during beta so sessions and sets can seed training evidence, with exercise matching and import limitations kept visible. |
| Pricing posture |
Strong has a known free tier, paid Pro features, and a lifetime purchase option in observed current evidence. |
Oved is in supervised beta. Public pricing should not be inferred from this page. |